HAVANA, Cuba, Apr 5 (ACN) Cuban President Miguel Díaz-Canel highlighted today on Twitter the good pace of trials with the Cuban drug NeuroEpo, developed by the Center for Molecular Immunology (CIM) to treat mild and moderate Alzheimer's cases.
After a meeting with researchers, he praised the health care services provided to patients suffering from dementia and Alzheimer's disease, both with a high incidence in Cuba.
In March, the Center for State Control of Medicines, Equipment and Medical Devices (CECMED) approved the Conditional Health Registration of NeuralCim—NeuroEpo's trade name—after evaluating the documentation submitted by CIM, which develops this molecule jointly with other BioCubaFarma institutions.
NeuroEpo is a nasal formulation of recombinant human erythropoietin (EPO) with a low content of sialic acid, an isoform similar in composition to the natural EPO produced in the central nervous system.
According to CIM specialists, the clinical trials produced encouraging results.
Cuban president praises progress of NeuroEpo trials
Nos reservamos el derecho de no publicar los comentario que incumplan con las normas de este sitio